Home Blood-Pressure Monitoring in Patients Receiving Sunitinib
Authors:
- Michel AziziMAMichel Azizi
- Antoine ChedidACAntoine Chedid
- Stéphane OudardSOStéphane Oudard
- 3 January 2008
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (1) , 95-97
Abstract
The use of sunitinib, an inhibitor of the split-kinase-domain family of receptor tyrosine kinases (including vascular endothelial growth factor receptor types 1 and 21), has been associated with a 15 to 25% incidence of hypertension in patients with advanced renal-cell carcinoma2,3; a similar incidence has been associated with other antiangiogenic drugs.3,4 We report on 14 consecutive patients with metastatic renal-cell carcinoma who were being treated with sunitinib and in whom home monitoring of blood pressure by teletransmission revealed a rapid, marked increase in blood pressure, an effect that was not detected by casual office measurement of blood pressure.Keywords
This publication has 5 references indexed in Scilit:
- 2007 Guidelines for the Management of Arterial HypertensionJournal Of Hypertension, 2007
- Sunitinib: From Rational Design to Clinical EfficacyJournal of Clinical Oncology, 2007
- Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-AnalysisAmerican Journal of Kidney Diseases, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Hypertension and targeted therapyTargeted Oncology, 2006